Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Trial StartSER-252Positive

AI Analysis

Summary

Serina Therapeutics announced completion of enrollment and dosing in Cohort 1 of its registrational trial for SER-252, a candidate for advanced Parkinson's Disease. This represents a milestone in the clinical development program.

Clinical Trial Data

Phase

Registrational

Outcome Details

Completion of enrollment and dosing in Cohort 1 of registrational trial

Importance:5/10

Sentiment:

0.50

Parkinson's DiseaseClinical TrialSER-252Enrollment Milestone

Related Companies

$SER

Read the original article

Published by yahoo_finance on July 23, 2026 10:00 AM

Read Original